A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Purple Biotech Ltd.
RECORDATI GROUP
Mayo Clinic
Xencor, Inc.
Novartis
Ohio State University Comprehensive Cancer Center
University of California, San Francisco
Virginia Commonwealth University
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
Delcath Systems Inc.
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Exelixis
Rutgers, The State University of New Jersey